Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 3/20 | 0.53 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26220771 | 1.00 | TGM2 (0.53) | TGM2GSTO1F13A1TGM1XDH | |
| SCHEMBL31336535 | 0.84 | TGM2 (0.53) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL26220773 | 0.84 | TGM2 (0.53) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL31336618 | 0.83 | TGM2 (0.49) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL26220306 | 0.83 | TGM2 (0.49) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL26220769 | 0.82 | TGM2 (0.56) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL31599360 | 0.82 | TGM2 (0.53) | TGM2GSTO1F13A1TGM1NR3C1 | |
| SCHEMBL25386283 | 0.81 | NR3C1 (0.50) | TGM2F13A1TGM1NR3C1EGFR | |
| SCHEMBL30590830 | 0.81 | NR3C1 (0.50) | TGM2F13A1TGM1NR3C1EGFR | |
| SCHEMBL30590826 | 0.78 | TGM2 (0.50) | TGM2GSTO1F13A1TGM1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171451-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| EP-4488276-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2025-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171451-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP4A11, CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TGM2 4139/4885GSTO1 4342/4885F13A1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.